Literature DB >> 11781839

Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells.

K Ohmine1, J Ota, M Ueda, S Ueno, K Yoshida, Y Yamashita, K Kirito, S Imagawa, Y Nakamura, K Saito, M Akutsu, K Mitani, Y Kano, N Komatsu, K Ozawa, H Mano.   

Abstract

Chronic myeloid leukemia (CML) is characterized by the clonal expansion of hematopoietic stem cells (HSCs). Without effective treatment, individuals in the indolent, chronic phase (CP) of CML undergo blast crisis (BC), the prognosis for which is poor. It is therefore important to clarify the mechanism underlying stage progression in CML. DNA microarray is a versatile tool for such a purpose. However, simple comparison of bone marrow mononuclear cells from individuals at different disease stages is likely to result in the identification of pseudo-positive genes whose change in expression only reflects the different proportions of leukemic blasts in bone marrow. We have therefore compared with DNA microarray the expression profiles of 3456 genes in the purified HSC-like fractions that had been isolated from 13 CML patients and healthy volunteers. Interestingly, expression of the gene for PIASy, a potential inhibitor of STAT (signal transducer and activator of transcription) proteins, was down-regulated in association with stage progression in CML. Furthermore, forced expression of PIASy has induced apoptosis in a CML cell line. These data suggest that microarray analysis with background-matched samples is an efficient approach to identify molecular events underlying the stage progression in CML.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11781839     DOI: 10.1038/sj.onc.1205029

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

Review 1.  Microarray-based expression profiling of normal and malignant immune cells.

Authors:  Rheem D Medh
Journal:  Endocr Rev       Date:  2002-06       Impact factor: 19.871

2.  A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.

Authors:  Mario Notari; Paolo Neviani; Ramasamy Santhanam; Bradley W Blaser; Ji-Suk Chang; Annamaria Galietta; Anne E Willis; Denis C Roy; Michael A Caligiuri; Guido Marcucci; Danilo Perrotti
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

Review 3.  miRNAs as Biomarkers in Chronic Myelogenous Leukemia.

Authors:  Kasuen Kotagama; Yung Chang; Marco Mangone
Journal:  Drug Dev Res       Date:  2015-08-18       Impact factor: 4.360

4.  Piezophysiology of genome wide gene expression levels in the yeast Saccharomyces cerevisiae.

Authors:  Hitoshi Iwahashi; Hisayo Shimizu; Mine Odani; Yasuhiko Komatsu
Journal:  Extremophiles       Date:  2003-04-09       Impact factor: 2.395

5.  Gene expression changes associated with progression and response in chronic myeloid leukemia.

Authors:  Jerald P Radich; Hongyue Dai; Mao Mao; Vivian Oehler; Jan Schelter; Brian Druker; Charles Sawyers; Neil Shah; Wendy Stock; Cheryl L Willman; Stephen Friend; Peter S Linsley
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

6.  Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events.

Authors:  Hani Kim; Lisa C Gillis; Jordan D Jarvis; Stuart Yang; Kai Huang; Sandy Der; Dwayne L Barber
Journal:  BMC Cancer       Date:  2011-12-28       Impact factor: 4.430

7.  PIAS4 is an activator of hypoxia signalling via VHL suppression during growth of pancreatic cancer cells.

Authors:  W Chien; K L Lee; L W Ding; P Wuensche; H Kato; N B Doan; L Poellinger; J W Said; H P Koeffler
Journal:  Br J Cancer       Date:  2013-09-03       Impact factor: 7.640

Review 8.  Gene expression profiling: from microarrays to medicine.

Authors:  Ashani T Weeraratna; James E Nagel; Valeria de Mello-Coelho; Dennis D Taub
Journal:  J Clin Immunol       Date:  2004-05       Impact factor: 8.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.